Man Group plc Takes Position in Thermo Fisher Scientific Inc. $TMO

Man Group plc acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, Holdings Channel.com reports. The fund acquired 195,160 shares of the medical research company’s stock, valued at approximately $97,845,000.

Other large investors have also added to or reduced their stakes in the company. High Note Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $28,000. Kilter Group LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Birchwood Financial Partners Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth $29,000. Finally, Legacy Wealth Managment LLC ID boosted its position in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,493 shares of company stock valued at $43,950,381 over the last quarter. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of several analyst reports. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Morgan Stanley raised their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. Finally, Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Stock Down 0.1%

NYSE TMO opened at $627.96 on Wednesday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The stock has a market capitalization of $232.19 billion, a PE ratio of 33.78, a PEG ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The business’s 50-day moving average is $548.75 and its 200 day moving average is $510.05.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.